A Phase II Trial of Osimertinib and Abemaciclib With a Focus on Non-Small Cell Lung Cancer Patients With EGFR Activating Mutations With Osimertinib Resistance
Latest Information Update: 07 Aug 2024
At a glance
- Drugs Abemaciclib (Primary) ; Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Proof of concept; Therapeutic Use
- 05 Aug 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.
- 05 Aug 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 07 Aug 2023 Planned End Date changed from 1 Apr 2023 to 1 Dec 2023.